Malign Mezotelyoma
Özet
Malign mezotelyoma (MM), agresif seyirli ve kısa sağkalım süresi nedeniyle etkin bir takip süreci gerektiren, asbest maruziyeti ile ilişkili nadir bir kanser türüdür. Malign plevral mezotelyoma (MPM) ve malign peritoneal mezotelyoma (MPeM) en sık görülen alt tipler olup, takip planı hastalığın evresine, tedavi yaklaşımına ve hasta özelliklerine göre bireyselleştirilmelidir. MPM hastalarında takip, remisyona giren hastalarda nükslerin erken tespiti ve tedaviye bağlı komplikasyonların yönetimi açısından düzenli aralıklarla klinik değerlendirme, laboratuvar testleri ve görüntüleme yöntemlerini içermelidir. MPeM hastalarında ise cerrahi sonrası komplikasyonların izlenmesi ve semptom yönetimi ön planda tutulur. Ayrıca, nadir görülen perikardiyal ve tunika vajinalis mezotelyoması gibi alt tiplerde multidisipliner iş birliği ile bireyselleştirilmiş takip protokolleri gereklidir. MM hastalarında takip, yalnızca hastalık progresyonunun izlenmesini değil, aynı zamanda yaşam kalitesini artırmayı ve komplikasyonları yönetmeyi amaçlayan hasta merkezli bir yaklaşımı zorunlu kılmaktadır.
Malignant mesothelioma (MM) is a rare type of cancer associated with asbestos exposure that requires an effective follow-up process due to its aggressive course and short survival time. Malignant pleural mesothelioma (MPM) and malignant peritoneal mesothelioma (MPeM) are the most common subtypes and the follow-up plan should be individualized according to the stage of disease, treatment approach and patient characteristics. Follow-up in MPM patients should include regular clinical evaluation, laboratory tests and imaging methods for early detection of relapses in patients in remission and management of treatment-related complications. In MPeM patients, monitoring of postoperative complications and symptom management are prioritized. In addition, individualized follow-up protocols with multidisciplinary collaboration are required in rare subtypes such as pericardial and tunica vaginalis mesothelioma. Follow-up in MM patients requires a patient-centered approach that aims not only to monitor disease progression but also to improve quality of life and manage complications.
Referanslar
Pouliquen DL, Kopecka J. Malignant Mesothelioma. Cancers (Basel). 2021;13(14).
Cunha P, Luz Z, Seves I, Sousa C, Skiappa, Ribeiro L, et al. [Malignant peritoneal mesothelioma -- diagnostic and therapeutic difficulties]. Acta Med Port. 2002;15(5):383-6.
Hiltbrunner S, Fleischmann Z, Sokol ES, Zoche M, Felley-Bosco E, Curioni-Fontecedro A. Genomic landscape of pleural and peritoneal mesothelioma tumours. Br J Cancer. 2022;127(11):1997-2005.
Letica-Kriegel AS, Leinwand JC, Sonett JR, Gorenstein LA, Taub RN, Chabot JA, et al. 50 Patients with Malignant Mesothelioma of Both the Pleura and Peritoneum: A Single-Institution Experience. Ann Surg Oncol. 2020;27(1):205-13.
Enewold L, Sharon E, Thomas A. Patterns of care and survival among patients with malignant mesothelioma in the United States. Lung Cancer. 2017;112:102-8.
Meyerhoff RR, Yang CF, Speicher PJ, Gulack BC, Hartwig MG, D'Amico TA, et al. Impact of mesothelioma histologic subtype on outcomes in the Surveillance, Epidemiology, and End Results database. J Surg Res. 2015;196(1):23-32.
Herndon JE, Green MR, Chahinian AP, Corson JM, Suzuki Y, Vogelzang NJ. Factors predictive of survival among 337 patients with mesothelioma treated between 1984 and 1994 by the Cancer and Leukemia Group B. Chest. 1998;113(3):723-31.
Edwards JG, Abrams KR, Leverment JN, Spyt TJ, Waller DA, O'Byrne KJ. Prognostic factors for malignant mesothelioma in 142 patients: validation of CALGB and EORTC prognostic scoring systems. Thorax. 2000;55(9):731-5.
Mikulski SM, Costanzi JJ, Vogelzang NJ, McCachren S, Taub RN, Chun H, et al. Phase II trial of a single weekly intravenous dose of ranpirnase in patients with unresectable malignant mesothelioma. J Clin Oncol. 2002;20(1):274-81.
Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel E, Ruffie P, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol. 2003;21(14):2636-44.
Baas P, Scherpereel A, Nowak AK, Fujimoto N, Peters S, Tsao AS, et al. First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial. Lancet. 2021;397(10272):375-86.
Schumann SO, Kocher G, Minervini F. Epidemiology, diagnosis and treatment of the malignant pleural mesothelioma, a narrative review of literature. J Thorac Dis. 2021;13(4):2510-23.
Hoeg BL, Bidstrup PE, Karlsen RV, Friberg AS, Albieri V, Dalton SO, et al. Follow-up strategies following completion of primary cancer treatment in adult cancer survivors. Cochrane Database Syst Rev. 2019;2019(11).
Kindler HL, Ismaila N, Armato SG, 3rd, Bueno R, Hesdorffer M, Jahan T, et al. Treatment of Malignant Pleural Mesothelioma: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2018;36(13):1343-73.
Lauk O, Neuer T, Battilana B, Inci I, Furrer K, Weder W, et al. Proposal for a new local recurrence score in patients with recurrent malignant pleural mesothelioma. J Thorac Dis. 2022;14(8):2835-44.
Woolhouse I, Bishop L, Darlison L, de Fonseka D, Edey A, Edwards J, et al. BTS guideline for the investigation and management of malignant pleural mesothelioma. BMJ Open Respir Res. 2018;5(1):e000266.
Popat S, Baas P, Faivre-Finn C, Girard N, Nicholson AG, Nowak AK, et al. Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up(☆). Ann Oncol. 2022;33(2):129-42.
van Zandwijk N. Clinical practice guidelines for malignant pleural mesothelioma. J Thorac Dis. 2013;5(6):724-5.
Patz EF, Jr., Shaffer K, Piwnica-Worms DR, Jochelson M, Sarin M, Sugarbaker DJ, et al. Malignant pleural mesothelioma: value of CT and MR imaging in predicting resectability. AJR Am J Roentgenol. 1992;159(5):961-6.
Banna GL, Addeo A, Zygoura P, Tsourti Z, Popat S, Curioni-Fontecedro A, et al. A prognostic score for patients with malignant pleural mesothelioma (MPM) receiving second-line immunotherapy or chemotherapy in the ETOP 9-15 PROMISE-meso phase III trial. Lung Cancer. 2022;169:77-83.
Byrne MJ, Nowak AK. Modified RECIST criteria for assessment of response in malignant pleural mesothelioma. Ann Oncol. 2004;15(2):257-60.
Fortin M, Tremblay A. Pleural controversies: indwelling pleural catheter vs. pleurodesis for malignant pleural effusions. J Thorac Dis. 2015;7(6):1052-7.
Brims F, Gunatilake S, Lawrie I, Marshall L, Fogg C, Qi C, et al. Early specialist palliative care on quality of life for malignant pleural mesothelioma: a randomised controlled trial. Thorax. 2019;74(4):354-61.
Luna J, Bobo A, Cabrera-Rodriguez JJ, Pagola M, Martin-Martin M, Ruiz MAG, et al. GOECP/SEOR clinical guidelines on radiotherapy for malignant pleural mesothelioma. World J Clin Oncol. 2021;12(8):581-608.
Jain V, Berman AT. Radiation Pneumonitis: Old Problem, New Tricks. Cancers (Basel). 2018;10(7).
Borrelli MR, Shen AH, Lee GK, Momeni A, Longaker MT, Wan DC. Radiation-Induced Skin Fibrosis: Pathogenesis, Current Treatment Options, and Emerging Therapeutics. Ann Plast Surg. 2019;83(4S Suppl 1):S59-S64.
Battifora H, McCaughey W. Tumors of the serosal membranes. Armed Forces Institute of Pathology. 1995.
Feldman AL, Libutti SK, Pingpank JF, Bartlett DL, Beresnev TH, Mavroukakis SM, et al. Analysis of factors associated with outcome in patients with malignant peritoneal mesothelioma undergoing surgical debulking and intraperitoneal chemotherapy. J Clin Oncol. 2003;21(24):4560-7.
Baratti D, Kusamura S, Martinetti A, Seregni E, Oliva DG, Laterza B, et al. Circulating CA125 in patients with peritoneal mesothelioma treated with cytoreductive surgery and intraperitoneal hyperthermic perfusion. Ann Surg Oncol. 2007;14(2):500-8.
Mezei G, Chang ET, Mowat FS, Moolgavkar SH. Epidemiology of mesothelioma of the pericardium and tunica vaginalis testis. Ann Epidemiol. 2017;27(5):348-59 e11.
Martinez-Giron R, Pantanowitz L, Martinez-Torre S, Pantanowitz J. Sudden cardiac death due to primary malignant pericardial mesothelioma: Brief report and literature review. Respir Med Case Rep. 2019;26:185-8.
